Therapeutic delivery systems for rheumatoid arthritis based on hydrogel carriers

Fabiola A Chapa-Villarreal¹, Madeleine Stephens², Rachel Pavlicin², Micaela Beussman³, Nicholas A Peppas⁴

Affiliations

¹ Department of Chemical Engineering, The University of Texas at Austin, 200 E. Dean Keeton St. Stop C0400, Austin TX, USA, 78712; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712.
² Department of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712.
³ Department of Chemical Engineering, The University of Texas at Austin, 200 E. Dean Keeton St. Stop C0400, Austin TX, USA, 78712.
⁴ Department of Chemical Engineering, The University of Texas at Austin, 200 E. Dean Keeton St. Stop C0400, Austin TX, USA, 78712; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712; Department of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712; Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave. Stop A1900, Austin TX, USA, 78712; Department of Surgery and Perioperative Care, Dell Medical School, 1601 Trinity St., Bldg. B, Stop Z0800, Austin TX, USA, 78712; Department of Pediatrics, Dell Medical School, 1400 Barbara Jordan Blvd., Austin TX, USA, 78723. Electronic address: peppas@che.utexas.edu.

PMID: 38548104
DOI: 10.1016/j.addr.2024.115300

Review

Therapeutic delivery systems for rheumatoid arthritis based on hydrogel carriers

Fabiola A Chapa-Villarreal et al. Adv Drug Deliv Rev. 2024 May.

. 2024 May:208:115300.

doi: 10.1016/j.addr.2024.115300. Epub 2024 Mar 26.

Authors

Fabiola A Chapa-Villarreal¹, Madeleine Stephens², Rachel Pavlicin², Micaela Beussman³, Nicholas A Peppas⁴

Affiliations

¹ Department of Chemical Engineering, The University of Texas at Austin, 200 E. Dean Keeton St. Stop C0400, Austin TX, USA, 78712; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712.
² Department of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712.
³ Department of Chemical Engineering, The University of Texas at Austin, 200 E. Dean Keeton St. Stop C0400, Austin TX, USA, 78712.
⁴ Department of Chemical Engineering, The University of Texas at Austin, 200 E. Dean Keeton St. Stop C0400, Austin TX, USA, 78712; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712; Department of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin TX, USA, 78712; Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave. Stop A1900, Austin TX, USA, 78712; Department of Surgery and Perioperative Care, Dell Medical School, 1601 Trinity St., Bldg. B, Stop Z0800, Austin TX, USA, 78712; Department of Pediatrics, Dell Medical School, 1400 Barbara Jordan Blvd., Austin TX, USA, 78723. Electronic address: peppas@che.utexas.edu.

PMID: 38548104
DOI: 10.1016/j.addr.2024.115300

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease suffered by millions of people worldwide. It can significantly affect the patient's quality of life by damaging not only the joints but also organs such as the lungs and the heart. RA is normally treated using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologics. These active agents often cause side effects and offer low efficacy due to their lack of specificity and limited retention time. In an attempt to improve RA treatments, hydrogel-based systems have been proposed as drug delivery carriers. Due to their exceptional adaptability and biocompatibility, hydrogels have the potential of enhancing the delivery of RA therapy through different administration routes in an efficient and effective manner. In this review, we explore the application of hydrogel systems as potential carriers in RA treatment. Additionally, we discuss recent work in the field and highlight the required hydrogel properties, depending on the administration route. The outstanding potential of hydrogel systems as carriers for RA was demonstrated; however, there is extensive research yet to be done to improve available treatments for RA.

Keywords: Hydrogel; Intra-articular; Oral; Parenteral; Rheumatoid arthritis; Transdermal.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Therapeutic delivery systems for rheumatoid arthritis based on hydrogel carriers

Affiliations

Therapeutic delivery systems for rheumatoid arthritis based on hydrogel carriers

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical